- •Mistral Large 2512 argues HOLD because The original short thesis for ABBV remains intact. Price is holding above critical support levels ($247.56-$252.43), and the technical structure (RSI, MACD, and moving averages) supports a continuation of the downward trend. The European Commission approval for TEPKINLY has not materially altered the technical outlook, and the stock's underperformance relative to SPY and XLV reinforces the short case.
- •What changed: ABBV has held above critical support levels ($247.56-$252.43) and remains within the original technical structure. The European Commission approval for TEPKINLY introduced a potential short-term catalyst but has not materially altered the technical outlook. The stock's underperformance relative to SPY and XLV reinforces the short thesis.
The original short thesis for ABBV remains intact. Price is holding above critical support levels ($247.56-$252.43), and the technical structure (RSI, MACD, and moving averages) supports a continuation of the downward trend. The European Commission approval for TEPKINLY has not materially altered the technical outlook, and the stock's underperformance relative to SPY and XLV reinforces the short case.
The original short thesis remains intact: ABBV was entered near 52-week highs with daily momentum already showing signs of rolling over (RSI falling, MACD histogram decaying). The TEPKINLY EU approval was a known catalyst that appears already priced in, as the stock has failed to break out despite the news. The 4h MACD histogram is now negative and falling, confirming bearish momentum is building at the primary timeframe, while the 1d RSI continues to decline from overbought levels. With the stop at $262 providing a defined risk and the target at $240 still achievable within the remaining horizon, the risk/reward remains favorable.
The short thesis remains intact: ABBV is pinned just under 4h/1day resistance $255.99 near its 52-week high with an extreme P/E of 124.9, and even a bullish TEPKINLY EU approval failed to produce acceptance above resistance. Waning 4h MACD momentum and non-confirming sector (XLV flat) support a mean-reversion move toward the $240 target, and the stop at $262 above resistance is not threatened with price -0.7% onside.
No model argued for EXIT.
- →The most likely reason the HOLD verdict is wrong is if price reclaims the resistance level at $255.99, invalidates the short thesis, and breaks above the stop at $262.00, confirming a failed breakdown and reopening the path toward higher targets.
Individual Model Review
The short thesis remains intact: ABBV is pinned just under 4h/1day resistance $255.99 near its 52-week high with an extreme P/E of 124.9, and even a bullish TEPKINLY EU approval failed to produce acceptance above resistance. Waning 4h MACD momentum and non-confirming sector (XLV flat) support a mean-reversion move toward the $240 target, and the stop at $262 above resistance is not threatened with price -0.7% onside.
The short thesis remains intact: ABBV is pinned just under 4h/1day resistance $255.99 near its 52-week high with an extreme P/E of 124.9, and even a bullish TEPKINLY EU approval failed to produce acceptance above resistance. Waning 4h MACD momentum and non-confirming sector (XLV flat) support a mean-reversion move toward the $240 target, and the stop at $262 above resistance is not threatened with price -0.7% onside.
▼ Click to expandABBV sits above all major moving averages with RSI 63-67 in a bullish regime, and a fresh positive drug catalyst plus a supportive SPY tape could drive acceptance above $255.99 toward the $262 stop. If the uptrend re-accelerates, a short fighting a strong large-cap healthcare uptrend near the highs risks stop-out before target.
▼ Click to expandThe original short thesis remains intact: ABBV was entered near 52-week highs with daily momentum already showing signs of rolling over (RSI falling, MACD histogram decaying). The TEPKINLY EU approval was a known catalyst that appears already priced in, as the stock has failed to break out despite the news. The 4h MACD histogram is now negative and falling, confirming bearish momentum is building at the primary timeframe, while the 1d RSI continues to decline from overbought levels. With the stop at $262 providing a defined risk and the target at $240 still achievable within the remaining horizon, the risk/reward remains favorable.
The original short thesis remains intact: ABBV was entered near 52-week highs with daily momentum already showing signs of rolling over (RSI falling, MACD histogram decaying). The TEPKINLY EU approval was a known catalyst that appears already priced in, as the stock has failed to break out despite the news. The 4h MACD histogram is now negative and falling, confirming bearish momentum is building at the primary timeframe, while the 1d RSI continues to decline from overbought levels. With the stop at $262 providing a defined risk and the target at $240 still achievable within the remaining horizon, the risk/reward remains favorable.
▼ Click to expandThe TEPKINLY EU approval introduces positive pipeline momentum that could drive a breakout above the $255.99 resistance and toward the 52-week high at $261.64. The 4h RSI is still rising (63.05) and the broader equity regime is bullish, creating a headwind for the short. If price cannot accelerate toward the target soon, the remaining time value decays and the risk/reward deteriorates as the stop remains wide relative to the remaining progress needed.
▼ Click to expandThe original short thesis for ABBV remains intact. Price is holding above critical support levels ($247.56-$252.43), and the technical structure (RSI, MACD, and moving averages) supports a continuation of the downward trend. The European Commission approval for TEPKINLY has not materially altered the technical outlook, and the stock's underperformance relative to SPY and XLV reinforces the short case.
The original short thesis for ABBV remains intact. Price is holding above critical support levels ($247.56-$252.43), and the technical structure (RSI, MACD, and moving averages) supports a continuation of the downward trend. The European Commission approval for TEPKINLY has not materially altered the technical outlook, and the stock's underperformance relative to SPY and XLV reinforces the short case.
▼ Click to expandThe exit case would strengthen if price reclaims the resistance level at $255.99, breaks above the stop at $262.00, or if the MACD histogram turns decisively positive, signaling a trend reversal. A material shift in the broader market regime or a bullish catalyst for ABBV could also invalidate the short thesis.
▼ Click to expandRun Summary
Intraday discovery triggered reanalysis on ABBV. Verdict: HOLD (0/3 EXIT). Conviction: 77.